Massachusetts is currently home to 3150 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378
Recruiting
This study will evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PDy) of novel immunotherapy combinations compared with immunotherapy monotherapy in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: GSK Investigational Site, Boston, Massachusetts
Conditions: Lung Cancer, Non-Small Cell
Register for Updates
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
NCT05392114
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
11/08/2024
Locations: Ionis Investigative Site, Boston, Massachusetts
Conditions: Hereditary Angioedema
Register for Updates
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT04910685
Recruiting
This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. Parts 1 and 2 will enroll patients with ISM. Patients enrolled in Part 1 or Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part.... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
11/08/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis
Register for Updates
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
NCT04768972
Recruiting
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Gender:
ALL
Ages:
10 years and above
Trial Updated:
11/08/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
NCT04653246
Recruiting
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
11/08/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
Register for Updates
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study
NCT04331769
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Register for Updates
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults with Eosinophilic Esophagitis
NCT06598462
Recruiting
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/07/2024
Locations: Research Site 1004, Boston, Massachusetts
Conditions: Eosinophilic Esophagitis (EoE)
Register for Updates
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
NCT05287126
Recruiting
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment), or until marketing authorization is obtained in the participant's country, which... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
11/07/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Ulcerative Colitis
Register for Updates
Clinical and Basic Investigations Into Congenital Disorders of Glycosylation
NCT04199000
Recruiting
The purpose of this research is to study the natural history of congenital disorders of glycosylation and its causes and treatments.
Gender:
ALL
Ages:
All
Trial Updated:
11/07/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Congenital Disorders of Glycosylation
Register for Updates
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
NCT06551129
Recruiting
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: Analysis Group Inc., Boston, Massachusetts
Conditions: Obstructive Hypertrophic Cardiomyopathy
Register for Updates
AB-2100, an Integrated Circuit T (ICT) Cell Therapy in Patients with Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
NCT06245915
Recruiting
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: Dana Farber Cancer Institue, Boston, Massachusetts
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Register for Updates
A Text Messaging Intervention to Reduce Perinatal Depression Risk
NCT06117397
Recruiting
Development and preliminary testing of a text messaging intervention that will reduce the risk of a major depressive episode and worsening depressive symptoms in perinatal individuals. The system will screen pregnant individuals, send tailored text messages with links to enhanced content, and will include a peer chat function.This accessible text platform will leverage both the ease of use inherent in text messages and the power of enhanced content drawn evidence from based behavioral interventi... Read More
Gender:
FEMALE
Ages:
Between 16 years and 45 years
Trial Updated:
11/06/2024
Locations: UMass Chan Medical School, Worcester, Massachusetts
Conditions: Major Depressive Episode
Register for Updates